INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,312 | -99.8% | 236 | -99.7% | 0.00% | -100.0% |
Q2 2023 | $5,761,901 | +19.1% | 90,997 | +1.9% | 0.04% | +26.7% |
Q1 2023 | $4,836,461 | +243.4% | 89,316 | +235.6% | 0.03% | +275.0% |
Q4 2022 | $1,408,519 | -38.2% | 26,616 | -45.7% | 0.01% | -38.5% |
Q3 2022 | $2,279,000 | -23.6% | 48,976 | -6.3% | 0.01% | -27.8% |
Q2 2022 | $2,982,000 | +106.8% | 52,246 | +121.7% | 0.02% | +50.0% |
Q1 2022 | $1,442,000 | +119.1% | 23,562 | +46.1% | 0.01% | +71.4% |
Q2 2021 | $658,000 | +261.5% | 16,124 | +200.7% | 0.01% | +250.0% |
Q1 2021 | $182,000 | -9.0% | 5,362 | -14.9% | 0.00% | -33.3% |
Q4 2020 | $200,000 | -73.9% | 6,300 | -78.9% | 0.00% | -72.7% |
Q3 2020 | $765,000 | +238.5% | 29,820 | +238.9% | 0.01% | +175.0% |
Q2 2020 | $226,000 | -8.9% | 8,800 | -73.5% | 0.00% | -20.0% |
Q3 2019 | $248,000 | -2.7% | 33,234 | +69.4% | 0.01% | 0.0% |
Q2 2019 | $255,000 | -52.2% | 19,620 | -55.3% | 0.01% | -70.6% |
Q1 2019 | $534,000 | -17.7% | 43,872 | -23.0% | 0.02% | -45.2% |
Q4 2018 | $649,000 | +4892.3% | 56,983 | +9397.2% | 0.03% | +3000.0% |
Q3 2018 | $13,000 | -92.4% | 600 | -93.8% | 0.00% | -88.9% |
Q2 2018 | $170,000 | +27.8% | 9,641 | +53.0% | 0.01% | +12.5% |
Q1 2018 | $133,000 | -83.0% | 6,302 | -88.3% | 0.01% | -80.5% |
Q4 2017 | $781,000 | +688.9% | 53,932 | +757.6% | 0.04% | +583.3% |
Q3 2017 | $99,000 | -38.5% | 6,289 | -41.0% | 0.01% | -53.8% |
Q4 2016 | $161,000 | -74.6% | 10,664 | -74.3% | 0.01% | -68.3% |
Q3 2016 | $633,000 | +5175.0% | 41,526 | +13742.0% | 0.04% | +4000.0% |
Q2 2016 | $12,000 | -96.6% | 300 | -97.7% | 0.00% | -95.0% |
Q1 2016 | $357,000 | -77.5% | 12,836 | -56.6% | 0.02% | -78.5% |
Q4 2015 | $1,590,000 | +264.7% | 29,553 | +171.7% | 0.09% | +322.7% |
Q3 2015 | $436,000 | -26.1% | 10,879 | -41.1% | 0.02% | -24.1% |
Q2 2015 | $590,000 | +121.0% | 18,463 | +64.8% | 0.03% | +123.1% |
Q1 2015 | $267,000 | – | 11,200 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |